Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus 0.03% ointment for intractable allergic conjunctivitis
NCT00443105Phase 2Unknown
- Sponsor
- Shamir Medical Center
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Envarsus XR in allergic conjunctivitis (AC), sponsored by Shamir Medical Center. Status: unknown.
02
Drugs
Envarsus XR
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT00443105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00443105.